Literature DB >> 9419754

Epidermal growth factor enhances secretion of the ovarian tumor-associated cancer antigen CA125 from the human amnion WISH cell line.

I Konishi1, J L Fendrick, T H Parmley, J G Quirk, T J O'Brien.   

Abstract

OBJECTIVE: We studied the relation between epidermal growth factor (EGF)/epidermal growth factor receptor (EGFR) and CA125 production in WISH cells.
METHODS: We investigated quantitatively and immunohistochemically EGF-stimulated CA125 release from WISH cells and the effect of EGF on CA125 phosphorylation.
RESULTS: Immunohistochemical staining demonstrated that CA125 and EGFR expression on the plasma membrane of the WISH cells was closely correlated with cell density. The WISH cell monolayers (day 4) stained for CA125 in both the cytoplasm and plasma membrane. By day 8, cells began to form clumps in the surrounding monolayer that were positive for membrane-associated CA125 and EGFR, while the monolayer was almost negative for both molecules. Four-day and 8-day cells exposed to EGF demonstrated a loss of both CA125 and EGFR staining. Epidermal growth factor increased the secreted CA125 levels by 50% in day-4 cells but had no effect on day-8 cells. CA125 from WISH cells was phosphorylated, and EGF further enhanced this phosphorylation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 9419754     DOI: 10.1177/107155769400100118

Source DB:  PubMed          Journal:  J Soc Gynecol Investig        ISSN: 1071-5576


  8 in total

Review 1.  Understanding the Unique Attributes of MUC16 (CA125): Potential Implications in Targeted Therapy.

Authors:  Srustidhar Das; Surinder K Batra
Journal:  Cancer Res       Date:  2015-11-02       Impact factor: 12.701

2.  Membrane proximal ectodomain cleavage of MUC16 occurs in the acidifying Golgi/post-Golgi compartments.

Authors:  Srustidhar Das; Prabin D Majhi; Mona H Al-Mugotir; Satyanarayana Rachagani; Paul Sorgen; Surinder K Batra
Journal:  Sci Rep       Date:  2015-06-05       Impact factor: 4.379

Review 3.  Altered Mucins (MUC) trafficking in benign and malignant conditions.

Authors:  Suhasini Joshi; Sushil Kumar; Amit Choudhury; Moorthy P Ponnusamy; Surinder K Batra
Journal:  Oncotarget       Date:  2014-09-15

4.  Understanding the Correlation between Metabolic Regulator SIRT1 and Exosomes with CA-125 in Ovarian Cancer: A Clinicopathological Study.

Authors:  Sraddhya Roy; Ananya Das; Manisha Vernekar; Syamsundar Mandal; Nabanita Chatterjee
Journal:  Biomed Res Int       Date:  2022-04-20       Impact factor: 3.246

Review 5.  Deciphering the molecular nature of ovarian cancer biomarker CA125.

Authors:  Florian Weiland; Karina Martin; Martin K Oehler; Peter Hoffmann
Journal:  Int J Mol Sci       Date:  2012-08-22       Impact factor: 6.208

Review 6.  MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.

Authors:  Mildred Felder; Arvinder Kapur; Jesus Gonzalez-Bosquet; Sachi Horibata; Joseph Heintz; Ralph Albrecht; Lucas Fass; Justanjyot Kaur; Kevin Hu; Hadi Shojaei; Rebecca J Whelan; Manish S Patankar
Journal:  Mol Cancer       Date:  2014-05-29       Impact factor: 27.401

7.  Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.

Authors:  Zhuowei Gu; Yifeng He; Yue Zhang; Mo Chen; Keqi Song; Yuting Huang; Qing Li; Wen Di
Journal:  J Transl Med       Date:  2018-05-01       Impact factor: 5.531

Review 8.  Photoimmunotherapy of Ovarian Cancer: A Unique Niche in the Management of Advanced Disease.

Authors:  Shubhankar Nath; Mohammad Ahsan Saad; Michael Pigula; Joseph W R Swain; Tayyaba Hasan
Journal:  Cancers (Basel)       Date:  2019-11-27       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.